Literature DB >> 21233204

Generation, characterization, and epitope mapping of neutralizing and protective monoclonal antibodies against staphylococcal enterotoxin B-induced lethal shock.

Avanish K Varshney1, Xiaobo Wang, Emily Cook, Kaushik Dutta, Matthew D Scharff, Michael J Goger, Bettina C Fries.   

Abstract

T-cell stimulating activity of Staphylococcal enterotoxin B (SEB) is an important factor in the pathogenesis of certain staphylococcal diseases including SEB mediated shock. SEB is one of the most potent superantigens known and treatment of SEB induced shock remains a challenge. We generated and characterized murine monoclonal antibodies (mAbs) to SEB in mice. We tested mAbs neutralize mitogenic effects of SEB in vitro and in vivo with T-cell proliferation assays and 2 murine models for SEB induced lethal shock (SEBILS). Epitope mapping suggests that all these mAbs recognize conformational epitopes that are destroyed by deleting the C terminus of the protein. Further site-directed mutagenesis identified potential residues involved in binding to SEB that differ between Methicillin resistant and sensitive Staphylococcus aureus strains. Only mAb 20B1 was effective as a monotherapy in treating SEBILS in HLA DR3 transgenic mice, which exhibit enhanced sensitivity to SEB. It is noteworthy that mAbs, 14G8 and 6D3 were not protective when given alone in the HLA DR3 mice but their efficacy of protection could be greatly enhanced when mAbs were co-administered simultaneously. Our data suggest combinations of defined mAbs may constitute a better treatment strategy and provide a new insight for the development of passive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21233204      PMCID: PMC3059042          DOI: 10.1074/jbc.M110.212407

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Superantigen vaccines: a comparative study of genetically attenuated receptor-binding mutants of staphylococcal enterotoxin A.

Authors:  S Bavari; B Dyas; R G Ulrich
Journal:  J Infect Dis       Date:  1996-08       Impact factor: 5.226

2.  Development of engineered vaccines effective against structurally related bacterial superantigens.

Authors:  R G Ulrich; M A Olson; S Bavari
Journal:  Vaccine       Date:  1998-11       Impact factor: 3.641

3.  Crystal structure of microbial superantigen staphylococcal enterotoxin B at 1.5 A resolution: implications for superantigen recognition by MHC class II molecules and T-cell receptors.

Authors:  A C Papageorgiou; H S Tranter; K R Acharya
Journal:  J Mol Biol       Date:  1998-03-20       Impact factor: 5.469

4.  Rapid clearance of the bacterial superantigen staphylococcal enterotoxin B in vivo.

Authors:  R Vabulas; R Bittlingmaier; K Heeg; H Wagner; T Miethke
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

5.  The significance of superantigens.

Authors:  R G Ulrich
Journal:  Trends Microbiol       Date:  1998-04       Impact factor: 17.079

Review 6.  Staphylococcal superantigens: do they play a role in sepsis?

Authors:  Silva Holtfreter; Barbara M Bröker
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2005 Jan-Feb       Impact factor: 4.291

7.  Staphylococcal enterotoxin B mutants (N23K and F44S): biological effects and vaccine potential in a mouse model.

Authors:  M A Woody; T Krakauer; B G Stiles
Journal:  Vaccine       Date:  1997-02       Impact factor: 3.641

8.  Staphylococcal enterotoxins condition cells of the innate immune system for Toll-like receptor 4 stimulation.

Authors:  Robert J Rossi; Guruprasaadh Muralimohan; Joseph R Maxwell; Anthony T Vella
Journal:  Int Immunol       Date:  2004-10-25       Impact factor: 4.823

9.  Cross-reactive antibodies prevent the lethal effects of Staphylococcus aureus superantigens.

Authors:  S Bavari; R G Ulrich; R D LeClaire
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

10.  Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B.

Authors:  H Li; A Llera; D Tsuchiya; L Leder; X Ysern; P M Schlievert; K Karjalainen; R A Mariuzza
Journal:  Immunity       Date:  1998-12       Impact factor: 31.745

View more
  42 in total

Review 1.  The potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections.

Authors:  Gordon Y C Cheung; Michael Otto
Journal:  Expert Opin Ther Targets       Date:  2012-04-25       Impact factor: 6.902

2.  Mechanisms mediating enhanced neutralization efficacy of staphylococcal enterotoxin B by combinations of monoclonal antibodies.

Authors:  Kaushik Dutta; Avanish K Varshney; Matthew C Franklin; Michael Goger; Xiaobo Wang; Bettina C Fries
Journal:  J Biol Chem       Date:  2015-01-08       Impact factor: 5.157

Review 3.  Potent Neutralization of Staphylococcal Enterotoxin B In Vivo by Antibodies that Block Binding to the T-Cell Receptor.

Authors:  Gang Chen; Hatice Karauzum; Hua Long; Danielle Carranza; Frederick W Holtsberg; Katie A Howell; Laura Abaandou; Bojie Zhang; Nick Jarvik; Wei Ye; Grant C Liao; Michael L Gross; Daisy W Leung; Gaya K Amarasinghe; M Javad Aman; Sachdev S Sidhu
Journal:  J Mol Biol       Date:  2019-03-27       Impact factor: 5.469

4.  Passive therapy with humanized anti-staphylococcal enterotoxin B antibodies attenuates systemic inflammatory response and protects from lethal pneumonia caused by staphylococcal enterotoxin B-producing Staphylococcus aureus.

Authors:  Melissa J Karau; Mulualem E Tilahun; Ashton Krogman; Barbara A Osborne; Richard A Goldsby; Chella S David; Jayawant N Mandrekar; Robin Patel; Govindarajan Rajagopalan
Journal:  Virulence       Date:  2016-12-07       Impact factor: 5.882

5.  Carbapenem-resistant Klebsiella pneumoniae exhibit variability in capsular polysaccharide and capsule associated virulence traits.

Authors:  Elizabeth Diago-Navarro; Liang Chen; Virginie Passet; Seth Burack; Amaia Ulacia-Hernando; Rosy Priya Kodiyanplakkal; Michael H Levi; Sylvain Brisse; Barry N Kreiswirth; Bettina C Fries
Journal:  J Infect Dis       Date:  2014-03-14       Impact factor: 5.226

6.  Structural basis for the neutralization and specificity of Staphylococcal enterotoxin B against its MHC Class II binding site.

Authors:  Tian Xia; Shuaiyi Liang; Huajing Wang; Shi Hu; Yuna Sun; Xiaojie Yu; Jun Han; Jun Li; Shangjing Guo; Jianxin Dai; Zhiyong Lou; Yajun Guo
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

7.  Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.

Authors:  Wenqian He; Caitlin E Mullarkey; J Andrew Duty; Thomas M Moran; Peter Palese; Matthew S Miller
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

Review 8.  Virulence Factor Targeting of the Bacterial Pathogen Staphylococcus aureus for Vaccine and Therapeutics.

Authors:  Trevor L Kane; Katelyn E Carothers; Shaun W Lee
Journal:  Curr Drug Targets       Date:  2018       Impact factor: 3.465

9.  Humanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycin.

Authors:  Avanish K Varshney; Xiaobo Wang; Jennifer MacIntyre; Richard S Zollner; Kerry Kelleher; Oleg V Kovalenko; Ximo Pechuan; Fergus R Byrne; Bettina C Fries
Journal:  J Infect Dis       Date:  2014-05-05       Impact factor: 5.226

10.  Detection and measurement of staphylococcal enterotoxin-like K (SEl-K) secretion by Staphylococcus aureus clinical isolates.

Authors:  Jorge L Aguilar; Avanish K Varshney; Xiaobo Wang; Lindsay Stanford; Matthew Scharff; Bettina C Fries
Journal:  J Clin Microbiol       Date:  2014-05-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.